Dopamine suppresses neuronal activity of Helisoma B5 neurons via a D2-like receptor, activating PLC and K channels.
Dopamine (DA) plays fundamental roles as a neurotransmitter and neuromodulator in the central nervous system. How DA modulates the electrical excitability of individual neurons to elicit various behaviors is of great interest in many systems. The buccal ganglion of the freshwater pond snail Helisoma trivolvis contains the neuronal circuitry for feeding and DA is known to modulate the feeding motor program in Helisoma. The buccal neuron B5 participates in the control of gut contractile activity and is surrounded by dopaminergic processes, which are expected to release DA. In order to study whether DA modulates the electrical activity of individual B5 neurons, we performed experiments on physically isolated B5 neurons in culture and on B5 neurons within the buccal ganglion in situ. We report that DA application elicited a strong hyperpolarization in both conditions and turned the electrical activity from a spontaneously firing state to an electrically silent state. Using the cell culture system, we demonstrated that the strong hyperpolarization was inhibited by the D2 receptor antagonist sulpiride and the phospholipase C (PLC) inhibitor U73122, indicating that DA affected the membrane potential of B5 neurons through the activation of a D2-like receptor and PLC. Further studies revealed that the DA-induced hyperpolarization was inhibited by the K channel blockers 4-aminopyridine and tetraethylammonium, suggesting that K channels might serve as the ultimate target of DA signaling. Through its modulatory effect on the electrical activity of B5 neurons, the release of DA in vivo may contribute to a neuronal output that results in a variable feeding motor program.
Department of Biology, Georgia State University, Atlanta, GA 30302, USA.
L R
LR
Zhong
L
L
Artinian
V
V
Rehder
D000818:Animals; D001552:Benzazepines / Q000494:pharmacology; D002478:Cells, Cultured; D004298:Dopamine / Q000494:pharmacology* / Q000502:physiology; D065127:Dopamine D2 Receptor Antagonists; D004963:Estrenes / Q000494:pharmacology; D008564:Membrane Potentials / Q000187:drug effects / Q000502:physiology*; D009061:Mouth Mucosa / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D015221:Potassium Channels / Q000502:physiology*; D011760:Pyrrolidinones / Q000494:pharmacology; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012908:Snails; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000502:physiology*
D001552:Benzazepines; D065127:Dopamine D2 Receptor Antagonists; D004963:Estrenes; D015221:Potassium Channels; D011760:Pyrrolidinones; D017448:Receptors, Dopamine D2; C534628:SCH 23390; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D010738:Type C Phospholipases; D004298:Dopamine